The DOI matches its Crossref record; 413 of the 413 references it cites were found in a registry or an index.
Understanding and targeting resistance mechanisms in cancer
Open accessAbstract
Resistance to cancer therapies has been a commonly observed phenomenon in clinical practice, which is one of the major causes of treatment failure and poor patient survival. The reduced responsiveness of cancer cells is a multifaceted phenomenon that can arise from genetic, epigenetic, and microenvironmental factors. Various mechanisms have been discovered and extensively studied, including drug inactivation, reduced intracellular drug accumulation by reduced uptake or increased efflux, drug target alteration, activation of compensatory pathways for cell survival, regulation of DNA repair and cell death, tumor plasticity, and the regulation from tumor microenvironments (TMEs). To overcome cancer resistance, a variety of strategies have been proposed, which are designed to enhance the effectiveness of cancer treatment or reduce drug resistance. These include identifying biomarkers that can predict drug response and resistance, identifying new targets, developing new targeted drugs, combination therapies targeting multiple signaling pathways, and modulating the TME. The present article focuses on the different mechanisms of drug resistance in cancer and the corresponding tackling approaches with recent updates. Perspectives on polytherapy targeting multiple resistance mechanisms, novel nanoparticle delivery systems, and advanced drug design tools for overcoming resistance are also reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Items 201–400 of 413
Casak, S. J., Donoghue, M., Fashoyin-Aje, L., Jiang, X., Rodriguez, L., Shen, Y.-L., Xu, Y., Jiang, X., Liu, J., Zhao, H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3407 · Cited by 181
The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation
Zahreddine, H. A., Culjkovic-Kraljacic, B., Assouline, S., Gendron, P., Romeo, A. A., Morris, S. J., Cormack, G., Jaquith, J. B., Cerchietti, L., Cocolakis, E., et al. (2014) · Nature · doi:10.1038/nature13283 · Cited by 179
Yang, C., Zhang, Y., Lin, S., Liu, Y., & Li, W. (2021) · Aging · doi:10.18632/aging.202774 · Cited by 174
Emerging roles for UDP-glucuronosyltransferases in drug resistance and cancer progression
Allain, E. P., Rouleau, M., Lévesque, E., & Guillemette, C. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0722-0 · Cited by 174
Zhang, W., Konopleva, M., Ruvolo, V. R., McQueen, T., Evans, R. L., Bornmann, W. G., McCubrey, J., Cortes, J., & Andreeff, M. (2008) · Leukemia · doi:10.1038/sj.leu.2405098 · Cited by 170
Cancer Metabolism and Drug Resistance
Rahman, M., & Hasan, M. (2015) · Metabolites · doi:10.3390/metabo5040571 · Cited by 170
Kancha, R. K., von Bubnoff, N., Peschel, C., & Duyster, J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1757 · Cited by 168
Fornari, F., Pollutri, D., Patrizi, C., La Bella, T., Marinelli, S., Casadei Gardini, A., Marisi, G., Baron Toaldo, M., Baglioni, M., Salvatore, V., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1464 · Cited by 168
Overcoming multidrug resistance in cancer: Recent progress in nanotechnology and new horizons
Majidinia, M., Mirza‐Aghazadeh‐Attari, M., Rahimi, M., Mihanfar, A., Karimian, A., Safa, A., & Yousefi, B. (2020) · IUBMB Life · doi:10.1002/iub.2215 · Cited by 167
ATP‐binding cassette (ABC) transporters in cancer: A review of recent updates
Wang, J., Wu, Z., Yang, Y., Teng, Q., Li, Y., Lei, Z., Jani, K., Kaushal, N., & Chen, Z. (2021) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12434 · Cited by 166
Self-citationContribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide
Zimmerman, E. I., Hu, S., Roberts, J. L., Gibson, A. A., Orwick, S. J., Li, L., Sparreboom, A., & Baker, S. D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3306 · Cited by 164
Peetla, C., Bhave, R., Vijayaraghavalu, S., Stine, A., Kooijman, E., & Labhasetwar, V. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100308n · Cited by 162
Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals
Szostakowska, M., Trębińska-Stryjewska, A., Grzybowska, E. A., & Fabisiewicz, A. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-5023-4 · Cited by 161
Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?
Bouwman, P., & Jonkers, J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0225 · Cited by 158
Sheng, W., Chen, C., Dong, M., Wang, G., Zhou, J., He, S., Li, Y., Zhang, J., & Ding, S. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.547 · Cited by 157
Tian, H., Lian, R., Li, Y., Liu, C., Liang, S., Li, W., Tao, T., Wu, X., Ye, Y., Yang, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18929-0 · Cited by 157
Cell membrane-coated nanocarriers: the emerging targeted delivery system for cancer theranostics
Bose, R. J., Paulmurugan, R., Moon, J. J., Lee, S., & Park, H. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.02.001 · Cited by 156
Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones
Martin, N. T., & Bell, J. C. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.04.001 · Cited by 154
Ślusarczyk, M., Lopez, M. H., Balzarini, J. M., Mason, M. D., Jiang, W. G., Blagden, S. P., Thompson, E., Ghazaly, E. A., & McGuigan, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401853a · Cited by 153
Katayama, R., Gong, B., Togashi, N., Miyamoto, M., Kiga, M., Iwasaki, S., Kamai, Y., Tominaga, Y., Takeda, Y., Kagoshima, Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11496-z · Cited by 151
O’Malley, D. M., Matulonis, U. A., Birrer, M. J., Castro, C. M., Gilbert, L., Vergote, I. B., Martin, L. P., Mantia-Smaldone, G. M., González-Martı́n, A., Bratos, R., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.01.037 · Cited by 149
Advances in Treatment of Wilson Disease
Aggarwal, A., & Bhatt, M. H. (2018) · Tremor and Other Hyperkinetic Movements · doi:10.5334/tohm.435 · Cited by 147
Zhang, L., He, X., Liu, X., Zhang, F., Huang, L. F., Potter, A., Xu, L., Zhou, W., Zheng, T., Luo, Z., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.07.009 · Cited by 146
The emergence of drug resistance to targeted cancer therapies: Clinical evidence
Sarmento‐Ribeiro, A. B., Scorilas, A., Gonçalves, A. C., Efferth, T., & Trougakos, I. P. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100646 · Cited by 145
Wang, H., Zhang, G., Zhang, H., Zhang, F., Zhou, B., Ning, F., Wang, H., Cai, S., & Du, J. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.12.004 · Cited by 144
Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy
Xiao, B., Ma, L., & Merlin, D. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1205583 · Cited by 142
The asymmetry of plasma membranes and their cholesterol content influence the uptake of cisplatin
Rivel, T., Ramseyer, C., & Yesylevskyy, S. O. (2019) · Scientific Reports · doi:10.1038/s41598-019-41903-w · Cited by 142
Wang, Y., Wang, Y., Qin, Z., Cai, S., Yu, L., Hu, H., & Zeng, S. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1887139 · Cited by 142
Redundant angiogenic signaling and tumor drug resistance
Gacche, R. N., & Assaraf, Y. G. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.01.002 · Cited by 141
Glutathione Transferases: Potential Targets to Overcome Chemoresistance in Solid Tumors
Pljesa-Ercegovac, M. S., Savic-Radojevic, A. R., Matic, M. G., Coric, V. M., Djukic, T. I., Radic, T. M., & Simic, T. P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123785 · Cited by 141
Chen, Y., Zhang, W., Huang, Y., Gao, F., Sha, X., & Fang, X. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.04.048 · Cited by 140
Zhang, C.-G., Zhu, W.-J., Liu, Y., Yuan, Z.-Q., Yang, S.-D., Chen, W.-L., Li, J., Zhou, X., Liu, C., & Zhang, X. (2016) · Scientific Reports · doi:10.1038/srep23859 · Cited by 137
Targeting HNRNPU to overcome cisplatin resistance in bladder cancer
Shi, Z., Hao, L., Han, X., Wu, Z., Pang, K., Dong, Y., Qin, J., Wang, G., Zhang, X., Xia, T., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01517-9 · Cited by 137
Self-citationLiu, X., Wu, Z., Guo, C., Guo, H., Su, Y., Chen, Q., Sun, C., Liu, Q., Chen, D., & Mu, H. (2021) · Drug Delivery · doi:10.1080/10717544.2021.2021324 · Cited by 136
Oncogenic extracellular vesicles in brain tumor progression
D’Asti, E., Garnier, D., Lee, T. H., Montermini, L., Meehan, B., & Rak, J. W. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00294 · Cited by 135
Martín, V., Sánchez‐Sánchez, A. M., Herrera, F., Gomez‐Manzano, C., Fueyo-Margareto, J., Vega, M. A. Á., Antolín, I., & Rodríguez, C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.188 · Cited by 133
Guo, Y., Zhang, X., Sun, W., Jia, H., Zhu, Y., Zhang, X., Zhou, N., & Wu, F. (2019) · Chemistry of Materials · doi:10.1021/acs.chemmater.9b03042 · Cited by 128
Regulatory functions of glutathioneS-transferase P1-1 unrelated to detoxification
Tew, K. D., & Townsend, D. M. (2011) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.552912 · Cited by 127
Inhibitors of the sphingomyelin cycle: Sphingomyelin synthases and sphingomyelinases
Adada, M. M., Luberto, C., & Canals, D. (2015) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2015.07.008 · Cited by 126
Sawers, L., Ferguson, M., Ihrig, B., Young, H. C., Chakravarty, P., Wolf, C. R., & Smith, G. C. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.386 · Cited by 126
Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance
Anreddy, N., Gupta, P., Kathawala, R. J., Patel, A. S., Wurpel, J. N. D., & Chen, Z. (2014) · Molecules · doi:10.3390/molecules190913848 · Cited by 126
Self-citationDrug metabolizing enzymes and their inhibitors' role in cancer resistance
Pathania, S., Bhatia, R., Baldi, A., Singh, R., & Rawal, R. K. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.117 · Cited by 126
Overcoming Glutathione S -Transferase P1–Related Cisplatin Resistance in Osteosarcoma
Pasello, M., Michelacci, F., Scionti, I., Hattinger, C. M., Zuntini, M., Caccuri, A. M., Scotlandi, K., Picci, P., & Serra, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5840 · Cited by 125
Zhu, Y., Tan, J., Xie, H., Wang, J., Meng, X., & Wang, R. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12769 · Cited by 125
Xu, Y., Lee, D.-K., Feng, Z., Xu, Y., Bu, W., Li, Y., Liao, L., & Xu, J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618091114 · Cited by 125
Wang, H., Mei, Y., Luo, C., Huang, Q., Wang, Z., Lu, G.-M., Qin, L., Sun, Z., Huang, C.-W., Yang, Z.-W., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4796 · Cited by 124
Exosomes as mediators of platinum resistance in ovarian cancer
Crow, J., Atay, S., Banskota, S., Artale, B., Schmitt, S., & Godwin, A. K. (2017) · Oncotarget · doi:10.18632/oncotarget.14440 · Cited by 123
UCH‐L1‐containing exosomes mediate chemotherapeutic resistance transfer in breast cancer
Ning, K., Wang, T., Sun, X., Zhang, P., Chen, Y., Jin, J., & Hua, D. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24614 · Cited by 123
Zhang, W., Feng, M., Zheng, G., et al. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.11.142 · Cited by 122
Deep, G., & Panigrahi, G. (2015) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v20.i5-6.130 · Cited by 121
Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights
Meador, C. B., & Hata, A. N. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107522 · Cited by 120
Drug-metabolizing enzymes: role in drug resistance in cancer
Kaur, G., Gupta, S. K., Singh, P., Ali, V., Kumar, V., & Verma, M. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02325-7 · Cited by 120
Compensatory angiogenesis and tumor refractoriness
Gacche, R. N. (2015) · Oncogenesis · doi:10.1038/oncsis.2015.14 · Cited by 119
Hansson, J., Berhane, K., Castro, V. M., Jungnelius, U., Mannervik, B., & Ringborg, U. K. (1991) · PubMed · Cited by 117
Meng, L., Xia, X., Yang, Y., Ye, J., Dong, W., Ma, P., Jin, Y., & Liu, Y. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.09.001 · Cited by 114
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆
Owen, C. N., Shoushtari, A. N., Chauhan, D., Palmieri, D. J., Lee, B., Rohaan, M. W., Mangana, J., Atkinson, V. G., Zaman, F. Y., Young, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.471 · Cited by 113
DMT1 Inhibitors Kill Cancer Stem Cells by Blocking Lysosomal Iron Translocation
Turcu, A. L., Versini, A., Khene, N., Gaillet, C., Cañeque, T., Müller, S., & Rodriguez, R. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202000159 · Cited by 109
Buxhofer‐Ausch, V., Secky, L., Wlcek, K., Svoboda, M., Kounnis, V., Briasoulis, E. C., Tzakos, A. G., Jaeger, W., & Thalhammer, T. (2013) · Journal of Drug Delivery · doi:10.1155/2013/863539 · Cited by 108
The tumour microenvironment as an integrated framework to understand cancer biology
Burgos‐Panadero, R., Lucantoni, F., Gamero‐Sandemetrio, E., de la Cruz‐Merino, L., Álvaro, T., & Noguera, R. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.07.010 · Cited by 107
Ji, N., Yang, Y., Cai, C., Lei, Z., Wang, J., Gupta, P., Shukla, S., Ambudkar, S. V., Kong, D., & Chen, Z. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.007 · Cited by 106
Self-citationBrandner, S., McAleenan, A., Kelly, C., Spiga, F., Cheng, H., Dawson, S., Schmidt, L., Faulkner, C., Wragg, C., Jefferies, S., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab105 · Cited by 102
Liu, Q., Li, J., Pu, G., Zhang, F., Liu, H., & Zhang, Y. (2015) · Drug Delivery · doi:10.3109/10717544.2015.1031295 · Cited by 101
Parrish, K. E., Pokorny, J. L., Mittapalli, R. K., Bakken, K. K., Sarkaria, J. N., & Elmquist, W. F. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.228213 · Cited by 101
NEDD4 and NEDD4L regulate Wnt signalling and intestinal stem cell priming by degrading LGR5 receptor
Novellasdemunt, L., Kucharska, A., Jamieson, C., Prange‐Barczynska, M., Baulies, A., Antas, P., van der Vaart, J., Gehart, H., Maurice, M. M., & Li, V. S. W. (2019) · The EMBO Journal · doi:10.15252/embj.2019102771 · Cited by 101
Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice
Mathieu, A., Remmelink, M., D’Haene, N., Penant, S., Gaussin, J., Ginckel, R. V., Darro, F., Robert Kiss, A., & Salmon, I. J. (2004) · Cancer · doi:10.1002/cncr.20571 · Cited by 99
Smitherman, P. K., Townsend, A. J., Kute, T. E., & Morrow, C. S. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.057729 · Cited by 98
Federici, L., Sterzo, C. L., Pezzola, S., Matteo, A. D., Scaloni, F., Federici, G., & Caccuri, A. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1314 · Cited by 95
Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches
Hu, X., & Zhang, Z. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.11.003 · Cited by 95
Watson, Z. L., Yamamoto, T. M., McMellen, A. N., Kim, H., Hughes, C. J., Brubaker, L. W., Post, M. D., Behbakht, K., & Bitler, B. G. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0758-2 · Cited by 94
Sun, L., Huang, C., Zhu, M., Guo, S., Gao, Q., Wang, Q., Chen, B., Li, R., Zhao, Y., Wang, M., et al. (2020) · Theranostics · doi:10.7150/thno.49717 · Cited by 94
Self-citationJia, L., Li, Z., Shen, J., Zheng, D., Tian, X., Guo, H., & Chang, P. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.05.010 · Cited by 93
Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC
Dagogo‐Jack, I., Rooney, M. M., Nagy, R. J., Lin, J. J., Chin, E. N., Ferris, L. A., Ackil, J., Lennerz, J. K., Lanman, R. B., Gainor, J. F., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.01.009 · Cited by 93
Absorption sites of orally administered drugs in the small intestine
Murakami, T. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1378176 · Cited by 92
CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro
Zhu, Z.-Y., Mu, Y., Qi, C., Wang, J., Xi, G., Guo, J., Ruoran, M., & ZHAO, F. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.2041 · Cited by 91
de la Fuente, M. T., Casanova, B., Moyano, J. V., Garcı́a-Gila, M., Sanz, L., Garcia-Marco, J. A., Silva, A., & Garcı́a-Pardo, A. (2002) · PubMed · Cited by 90
Miners, J. O., Chau, N., Rowland, A., Burns, K., McKinnon, R. A., Mackenzie, P. I., Tucker, G. T., Knights, K., & Kichenadasse, G. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.01.002 · Cited by 90
MicroRNA-17-5p regulates EMT by targeting vimentin in colorectal cancer
Kim, T. W., Lee, Y. S., Yun, N. H., Shin, C. H., Hong, H. K., Kim, H. H., & Cho, Y. B. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0940-5 · Cited by 90
Zeng, Y., Hu, Q., Zhuo, Q., Zhu, Y., Fan, G., Liu, M., Sun, Q., Zhang, Z., Liu, W., Xu, W., et al. (2020) · PubMed · Cited by 89
Mining the Tumor Phosphoproteome for Cancer Markers
Lim, Y. P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2243 · Cited by 88
Targeting Metabolic Reprogramming in Acute Myeloid Leukemia
Castro, I., Sampaio‐Marques, B., & Ludovico, P. (2019) · Cells · doi:10.3390/cells8090967 · Cited by 88
Vijayaraghavalu, S., Peetla, C., Lu, S., & Labhasetwar, V. D. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300281t · Cited by 85
Pluronic-Based Mixed Polymeric Micelles Enhance the Therapeutic Potential of Curcumin
Akbar, M. U., Zia, K. M., Nazir, A., Iqbal, J., Ejaz, S. A., & Akash, M. S. H. (2018) · AAPS PharmSciTech · doi:10.1208/s12249-018-1098-9 · Cited by 85
Doxorubicin and Lapatinib Combination Nanomedicine for Treating Resistant Breast Cancer
Wang, H., Li, F., Du, C., Wang, H., Mahato, R. I., & Huang, Y. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400687w · Cited by 83
He, X., Smith, S. E., Chen, S., Li, H., Wu, D., Meneses-Giles, P., Wang, Y., Hembree, M. J., Yi, K., Zhao, X., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109674 · Cited by 83
Li, H., Jia, L., Wu, F., & Huang, C. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0321 · Cited by 82
de la Fuente, M. T., Casanova, B., Moyano, J. V., Garcı́a-Gila, M., Sanz, L., Garcia-Marco, J. A., Silva, A., & Garcı́a-Pardo, A. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.3.495 · Cited by 82
Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy
Lu, X., Zhang, T., Zhu, S., Xun, Q., Tong, L.-J., Hu, X., Li, Y., Chan, S., Su, Y., Sun, Y., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00373 · Cited by 81
Liang, S.-Q., Marti, T. M., Dorn, P., Froment, L., Hall, S., Berezowska, S., Kocher, G. J., Schmid, R. A., & Peng, R. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.195 · Cited by 79
Zhang, X., Chen, X., Guo, Y., Gao, G., Wang, D., Wu, Y., Liu, J., Liang, G., Zhao, Y., & Wu, F. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202102059 · Cited by 79
Glutathione Transport Is a Unique Function of the ATP-binding Cassette Protein ABCG2
Brechbuhl, H. M., Gould, N. S., Kachadourian, R., Riekhof, W. R., Voelker, D. R., & Day, B. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.090506 · Cited by 78
SAU, A. C., Filomeni, G., Pezzola, S., D’Aguanno, S., Tregno, F. P., Urbani, A., Serra, M., Pasello, M., Picci, P., Federici, G., et al. (2011) · Molecular BioSystems · doi:10.1039/c1mb05295k · Cited by 78
Xiao, Y., Lin, F., & Lin, W.-C. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2015808118 · Cited by 78
Xiao, X., Wang, K., Zong, Q., Tu, Y., Dong, Y., & Yuan, Y. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120649 · Cited by 78
Inhibitors of cytochrome P450 (CYP) 1B1
Dutour, R., & Poirier, D. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.042 · Cited by 77
Zuo, J., Ishikawa, T., Boutros, S., Xiao, Z., Humtsoe, J. O., & Kramer, R. H. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0354 · Cited by 76
CANCER CHEMOTHERAPY AND DRUG METABOLISM
Riddick, D. S., Lee, C., Ramji, S., Chinje, E. C., Cowen, R. L., Williams, K. J., Patterson, A. V., Stratford, I. J., Morrow, C. S., Townsend, A. J., et al. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004374 · Cited by 76
Teegala, L. R., Garikapati, K. R., Reddy, S. G., Reddy, B. V. S., Yadav, J. S., Bhadra, U., & Bhadra, M. P. (2016) · Scientific Reports · doi:10.1038/srep35223 · Cited by 76
Advances in Treatment of Wilson Disease
Aggarwal, A., & Bhatt, M. H. (2017) · PubMed Central · doi:10.7916/d841881d · Cited by 76
Namba, T., Kodama, R., Moritomo, S., Hoshino, T., & Mizushima, T. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.172 · Cited by 75
Zhu, V. W., Klempner, S. J., & Ou, S. I. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.09.008 · Cited by 75
The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer
Ma, Y., Wang, L., Neitzel, L. R., Loganathan, S. N., Tang, N., Qin, L., Crispi, E. E., Guo, Y. P., Knapp, S., Beauchamp, R. D., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0453 · Cited by 74
Yan, L., Ding, B., Liu, H., Zhang, Y., Zeng, J., Hu, J., Yao, W., Gan, Y., An, R., Chen, Z., et al. (2019) · Theranostics · doi:10.7150/thno.37628 · Cited by 73
Self-citationXiong, M., Bao, Y., Du, X., Tan, Z., Jiang, Q., Wang, H., Zhu, Y., & Wang, J. (2013) · ACS Nano · doi:10.1021/nn403146t · Cited by 72
May, G. L., Wright, L. C., Dyne, M., Mackinnon, W. B., Fox, R. M., & Mountford, C. E. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910420517 · Cited by 72
Muralidharan-Chari, V., Kohan, H. G., Asimakopoulos, A. G., Sudha, T., Sell, S., Kannan, K., Boroujerdi, M., Davis, P. J., & Mousa, S. A. (2016) · Oncotarget · doi:10.18632/oncotarget.10395 · Cited by 71
Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition
Turajlic, S., Furney, S. J., Stamp, G., Rana, S., Ricken, G., Oduko, Y., Saturno, G., Springer, C. J., Hayes, A., Gore, M. E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu049 · Cited by 68
Drug metabolizing enzymes-associated chemo resistance and strategies to overcome it
Verma, H., Bahia, M. S., Choudhary, S., Singh, P. K., & Silakari, O. (2019) · Drug Metabolism Reviews · doi:10.1080/03602532.2019.1632886 · Cited by 67
Jacot, W., Lopez‐Crapez, E., Mollévi, C., Boissière‐Michot, F., Simony-Lafontaine, J., Ho-Pun-Cheung, A., Chartron, E., Theillet, C. G., Lemoine, A., Saffroy, R., et al. (2020) · Cancers · doi:10.3390/cancers12040828 · Cited by 67
A new paradigm for mechanobiological mechanisms in tumor metastasis
Torzilli, P. A., Bourne, J. W., Cigler, T., & Vincent, C. T. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.05.002 · Cited by 66
(2004) · PubMed · Cited by 66
Karachaliou, N., Codony‐Servat, J., Teixidó, C., Pilotto, S., Drozdowskyj, A., Codony, C., Giménez-Capitán, A. A., Molina‐Vila, M. Á., Bertrán-Alamillo, J., Gervais, R., et al. (2015) · Scientific Reports · doi:10.1038/srep17499 · Cited by 65
Targeted multidrug delivery system to overcome chemoresistance in breast cancer
Tang, Y., Soroush, F., Tong, Z., Kiani, M. F., & Wang, B. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s124770 · Cited by 65
ROR1 regulates chemoresistance in Breast Cancer via modulation of drug efflux pump ABCB1
Fultang, N., Illendula, A., Lin, J., Pandey, M. K., Klase, Z. A., & Peethambaran, B. (2020) · Scientific Reports · doi:10.1038/s41598-020-58864-0 · Cited by 65
Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling
WICKI, A. N., Mandalà, M., Massi, D., Taverna, D., Tang, H., Hemmings, B. A., & Xue, G. (2016) · Physiological Reviews · doi:10.1152/physrev.00024.2015 · Cited by 64
Loss of SLCO1B3 drives taxane resistance in prostate cancer
de Morrée, E. S., Böttcher, R., van Soest, R. J., Aghai, A., de Ridder, C. M., Gibson, A. A., Mathijssen, R. H. J., Burger, H., Wiemer, E. A. C., Sparreboom, A., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.251 · Cited by 64
Brunckhorst, M. K., Lerner, D. L., Wang, S., & Yu, Q. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.20563 · Cited by 62
Zigrino, P., Nischt, R., & Mauch, C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.168617 · Cited by 62
Isorhapontigenin (ISO) inhibits EMT through FOXO3A/METTL14/VIMENTIN pathway in bladder cancer cells
Zhang, N., Hua, X., Tu, H., Li, J., Zhang, Z., & Max, C. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.07.041 · Cited by 62
Olaussen, K. A., Commo, F., Tailler, M., Lacroix, L., Vitale, I., Raza, S. Q., Richon, C., Dessen, P., Lazar, V., Soria, J., et al. (2009) · Oncogene · doi:10.1038/onc.2009.277 · Cited by 61
van Roosmalen, I. A. M., Quax, W. J., & Kruyt, F. A. E. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.08.010 · Cited by 61
ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B–Driven Brainstem Glioma Model
Mittapalli, R. K., Chung, A. H., Parrish, K. E., Crabtree, D., Halvorson, K. G., Hu, G., Elmquist, W. F., & Becher, O. J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0093 · Cited by 61
Margolin, D. A., Silinsky, J., Grimes, C., Spencer, N. D., Aycock, M., Green, H., Cordova, J., Davis, N. K., Driscoll, T., & Li, L. (2011) · Neoplasia · doi:10.1593/neo.11324 · Cited by 60
Wang, Z., Liang, S., Lian, X., Liu, L., Zhao, S., Xuan, Q., Guo, L., Liu, H., Yang, Y., Dong, T., et al. (2015) · Scientific Reports · doi:10.1038/srep09301 · Cited by 60
Multi-Target ABC Transporter Modulators: What Next and Where to Go?
Stefan, S. M. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0185 · Cited by 60
Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
Ritter, V., Krautter, F., Klein, D., Jendrossek, V., & Rudner, J. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03971-7 · Cited by 60
Noia, V. D., D’Aveni, A., D’Argento, E., Rossi, S., Ghirardelli, P., Bortolotti, L., Vavassori, V., Bria, E., & Ceresoli, G. L. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100280 · Cited by 60
Exosome‑mediated gefitinib resistance in lung cancer HCC827 cells via delivery of miR‑21
Jing, C., Cao, H., Qin, X., Yu, S., Wu, J., Wang, Z., Ma, R., & Feng, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.8604 · Cited by 59
αvβ3 Integrin induces partial EMT independent of TGF-β signaling
Kariya, Y., Oyama, M., Suzuki, T., & Kariya, Y. (2021) · Communications Biology · doi:10.1038/s42003-021-02003-6 · Cited by 58
Gao, Y., Zhu, Y., Xu, X., Wang, F., Shen, W., Leng, X., Zhao, J., Liu, B., Wang, Y., & Liu, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.688070 · Cited by 58
Sivák, L., Šubr, V., Tomala, J., Říhová, B., Strohalm, J., Etrych, T., & Kovář, M. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.11.013 · Cited by 56
Patel, N., Garikapati, K. R., PANDITA, R. K., Singh, D. K., Pandita, T. K., Bhadra, U., & Bhadra, M. P. (2017) · Scientific Reports · doi:10.1038/s41598-017-02800-2 · Cited by 56
Liang, H., & Wang, M. (2019) · Cancer Management and Research · doi:10.2147/cmar.s212238 · Cited by 56
Tao, L.-Y., Liang, Y.-J., Wang, F., Chen, L., Yan, Y., Dai, C.-L., & Fu, L. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0949-1 · Cited by 55
Sale, M. J., Balmanno, K., Saxena, J., Ozono, E., Wojdyła, K., McIntyre, R. E., Gilley, R., Woroniuk, A., Howarth, K., Hughes, G. D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09438-w · Cited by 55
Huang, Z., Hua, D., & Du, X. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0956-2 · Cited by 53
Wang, X.-K., He, J., Xu, J.-H., Ye, S., Wang, F., Zhang, H., Huang, Z.-C., To, K. K. W., & Fu, L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3553 · Cited by 53
Endocrine Therapy for Breast Cancer in the Primary Care Setting
Awan, A. A., & Esfahani, K. (2018) · Current Oncology · doi:10.3747/co.25.4139 · Cited by 53
Miryala, S. K., Anbarasu, A., & Ramaiah, S. (2019) · Microbial Pathogenesis · doi:10.1016/j.micpath.2019.103668 · Cited by 53
Zou, W., Sarısözen, C., & Torchilin, V. P. (2016) · Journal of drug targeting · doi:10.1080/1061186x.2016.1236113 · Cited by 52
Lorente, J., Velandia, C., Leal, J. A., Garcia‐Mayea, Y., Lyakhovich, A., Kondoh, H., & LLeonart, M. E. (2017) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12337 · Cited by 52
Sato, H., Schoenfeld, A. J., Siau, E., Lu, Y. C., Tai, H., Suzawa, K., Kubota, D., Lui, A. J. W., Qeriqi, B., Mattar, M. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3321 · Cited by 52
Zou, M., Hu, X., Xu, B., Tong, T., Jing, Y., Xi, L., Zhou, W., Lu, J., Wang, X., Yang, X., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6861 · Cited by 51
Bertucci, F., Gonçalvès, A., Guillé, A., Adélaïde, J., Garnier, S., Carbuccia, N., Billon, E., Finetti, P., Sfumato, P., Monneur, A., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00897-9 · Cited by 51
Emerging roles of the solute carrier family in pancreatic cancer
Wu, Z., Xu, J., Chen, L., Meng, Q., Hua, J., Wang, W., Zhang, B., Liu, J., Yu, X., & Shi, S. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.356 · Cited by 49
Effect of aberrant DNA methylation on cancer stem cell properties
Mazloumi, Z., Farahzadi, R., Rafat, A., Asl, K. D., Karimipour, M., Montazer, M., Movassaghpour, A. A., Dehnad, A., & Charoudeh, H. N. (2022) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2022.104757 · Cited by 49
Nanomedicines for combating multidrug resistance of cancer
Zhu, Y., Jia, H., Duan, Q., & Wu, F. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1715 · Cited by 48
Lin, H., Hu, B., He, X., Mao, J., Wang, Y., Wang, J., Zhang, T., Zheng, J., Peng, Y., & Zhang, F. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113733 · Cited by 47
MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas
Abe, H., Natsumeda, M., Okada, M., Watanabe, J., Tsukamoto, Y., Kanemaru, Y., Yoshimura, J., Oishi, M., Hashizume, R., Kakita, A., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01568 · Cited by 46
Yu, Q., Xiao, W., Sun, S., Sohrabi, A., Liang, J., & Seidlits, S. K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.616580 · Cited by 46
Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance
Hofman, J., Vagiannis, D., Chen, S., & Guo, L. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109448 · Cited by 46
Yi, H., Liu, L., Sheng, N., Li, P., Pan, H., Cai, L., & Ma, Y. (2016) · Biomacromolecules · doi:10.1021/acs.biomac.6b00141 · Cited by 45
Landmann, H., Proia, D. A., He, S., Ogawa, L. S., Krämer, F., Beißbarth, T., Grade, M., Gaedcke, J., Ghadimi, M. B., Moll, U. M., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.378 · Cited by 44
García‐Martín, E., Pizarro, R. M., Martı́nez, C., Gutiérrez-Martı́n, Y., Pérez, G., Jover, R., & Agúndez, J. A. G. (2006) · Pharmacogenomics · doi:10.2217/14622416.7.4.575 · Cited by 44
New horizons in drug metabolism, pharmacokinetics and drug discovery.
Palmer, A. M. (2003) · PubMed · Cited by 44
Theunissen, J.-W. F., Cai, A. G., Bhatti, M. M., Cooper, A. B., Avery, A. D., Dorfman, R., Guelman, S. A., Levashova, Z. B., & Migone, T. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0471 · Cited by 44
CYP1B1 as a therapeutic target in cardio-oncology
Carrera, A. N., Grant, M. K. O., & Zordoky, B. N. M. (2020) · Clinical Science · doi:10.1042/cs20200310 · Cited by 44
Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer
Li, R., Zhang, J., Gilbert, S. M., Conejo-Garcia, J. R., & Mulé, J. J. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00483-z · Cited by 44
Singh, R., Fazal, Z., Corbet, A. K., Bikorimana, E., Rodriguez, J., Khan, E. M., Shahid, K., Freemantle, S. J., & Spinella, M. J. (2019) · Cancers · doi:10.3390/cancers11060796 · Cited by 42
Tratnyek, P. G., Bylaska, E. J., & Weber, E. J. (2017) · Environmental Science Processes & Impacts · doi:10.1039/c7em00053g · Cited by 41
Klánová, M., Lorková, L., Vít, O., Maswabi, B. C. L., Molinský, J., Pospíšilová, J., Vočková, P., Mavis, C. K., Latečková, L., Kulvait, V., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-159 · Cited by 40
Different Types of ROS1 Fusion Partners Yield Comparable Efficacy to Crizotinib
He, Y., Sheng, W., Hu, W., Lin, J., Liu, J., Yu, B., Mao, X., Zhang, L., Huang, J., & Wang, G. (2019) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504019x15509372008132 · Cited by 40
Autophagy Modulation and Cancer Combination Therapy: A Smart Approach in Cancer Therapy
Jeda, A. S., Ghabeshi, S., pour, Z. G. M., Jazaeri, E. O., Araiinejad, M., Sheikholeslami, F., Abdoli, M., Edalat, M., & Abdoli, A. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100512 · Cited by 40
de Jonge, M. J. A., Hamberg, P., Verweij, J., Savage, S., Suttle, A. B., Hodge, J. P., Arumugham, T., Pandite, L. N., & Hurwitz, H. I. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9885-8 · Cited by 38
Nanoparticle-siRNA: A Potential Strategy for Ovarian Cancer Therapy?
Aghamiri, S., Fallah-Mehrjardi, K., Shabani, S., Keshavarz‐Fathi, M., Kargar, S., & Rezaei, N. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0379 · Cited by 38
Bueschbell, B., Caniceiro, A. B., Suzano, P. M. S., Machuqueiro, M., Rosário‐Ferreira, N., & Moreira, I. S. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100811 · Cited by 38
Salomon, P. L., & Singh, R. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00028 · Cited by 37
Zhang, Q., & Peng, C. (2017) · Oncology Letters · doi:10.3892/ol.2017.7385 · Cited by 37
Combined radiation strategies for novel and enhanced cancer treatment
Kareliotis, G., Tremi, I., Kaitatzi, M., Drakaki, E., Serafetinides, A. A., Μakropoulou, Μ., & Georgakilas, A. G. (2020) · International Journal of Radiation Biology · doi:10.1080/09553002.2020.1787544 · Cited by 37
Tsujii, S., Serada, S., Fujimoto, M., Uemura, S., Namikawa, T., Nomura, T., Murakami, I., Hanazaki, K., & Naka, T. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0335 · Cited by 37
Dourado, D. F. A. R., Fernandes, P. A., Ramos, M. J., & Mannervik, B. (2013) · Biochemistry · doi:10.1021/bi4005705 · Cited by 35
Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
Sehgal, K., Piper‐Vallillo, A. J., Viray, H., Khan, A. M., Rangachari, D., & Costa, D. B. (2020) · Precision Cancer Medicine · doi:10.21037/pcm-20-20 · Cited by 35
DNA repair pathways and their roles in drug resistance for lung adenocarcinoma
Kara, A., Özgür, A., Nalbantoğlu, S., & Karadağ, A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06314-z · Cited by 35
Koshkin, P. A., Chistiakov, D. A., Nikitin, A. G., Konovalov, A. N., Potapov, A. A., Usachev, D. Y., Pitskhelauri, D. I., Kobyakov, G. L., Shishkina, L. V., & Chekhonin, V. P. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.01.001 · Cited by 32
Chemoinformatics and chemical genomics: potential utility of in silico methods
Valerio, L. G., & Choudhuri, S. (2012) · Journal of Applied Toxicology · doi:10.1002/jat.2804 · Cited by 32
The Emerging Role of the SLCO1B3 Protein in Cancer Resistance
Sun, R., Ying, Y., Tang, Z., Liu, T., Shi, F., Li, H., Guo, T., Huang, S., & Lai, R. (2019) · Protein and Peptide Letters · doi:10.2174/0929866526666190926154248 · Cited by 32
Zhang, Y., Wu, Z., Yang, Y., Wang, J., Li, J., Sun, Z., Teng, Q., Ashby, C. R., & Yang, D. (2020) · Cancers · doi:10.3390/cancers12113249 · Cited by 32
Self-citationDeoxycytidine Kinase (DCK) Mutations in Human Acute Myeloid Leukemia Resistant to Cytarabine
Wu, B., Mao, Z. J., Wang, Z., et al. (2021) · Acta Haematologica · doi:10.1159/000513696 · Cited by 32
Kawabata, S., Mercado-Matos, J., Hollander, M. C., Donahue, D., Wilson, W., Regales, L., Butaney, M., Pao, W. J., Wong, K., Janne, P. A., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.039 · Cited by 30
Qu, X., Davison, J., Du, L., Storer, B. E., Stirewalt, D. L., Heimfeld, S., Estey, E. H., Appelbaum, F. R., & Fang, M. (2015) · Epigenetics · doi:10.1080/15592294.2015.1048060 · Cited by 29
Osborne, M. J., de Oliveira, L. C., Volpon, L., Zahreddine, H. A., & Borden, K. L. B. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.11.007 · Cited by 29
Interplay of autophagy and cancer stem cells in hepatocellular carcinoma
Wong, M. M.-T., Chan, H.-Y., Aziz, N. A., Ramasamy, T. S., Bong, J. J., Ch’ng, E. S., Armon, S., Peh, S., & Teow, S. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06334-9 · Cited by 29
Dong, X.-D., Zhang, M., Cai, C.-Y., Teng, Q.-X., Wang, J.-Q., Fu, Y.-G., Cui, Q., Patel, K., Wang, D.-T., & Chen, Z.-S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.843829 · Cited by 29
Self-citationZhu, Y., Lin, X., Li, X., Wu, L., Chen, H., Wang, W., Xu, C., Shen, J., Wei, J., & Du, K. (2017) · Thoracic Cancer · doi:10.1111/1759-7714.12518 · Cited by 28
Use of Nanoparticles in Delivery of Nucleic Acids for Melanoma Treatment
Obeid, M. A., Aljabali, A. A. A., Rezigue, M. M., Amawi, H. A., Alyamani, H., Abdeljaber, S. N., & Ferro, V. A. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1205-7_41 · Cited by 28
New Perspectives of CYP1B1 Inhibitors in the Light of Molecular Studies
Mikstacka, R., & Dutkiewicz, Z. (2021) · Processes · doi:10.3390/pr9050817 · Cited by 27
Ye, D. M., Ye, S., Yu, S., Shu, F. F., Xu, S., Chen, Q. Q., Wang, Y. L., Tang, Z., & Pan, C. (2019) · Neoplasma · doi:10.4149/neo_2018_180820n633 · Cited by 26
Wu, Z., Teng, Q., Yang, Y., Acharekar, N., Wang, J., He, M. Y., Yoganathan, S., Lin, J., Wang, J., & Chen, Z. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.018 · Cited by 26
Self-citationSaleh, E., El‐Awady, R., Alim, M. A. A., & Wahab, A. H. A. A. (2009) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-009-9058-3 · Cited by 25
Al‐Abdulla, R., Perez‐Silva, L., Abete, L., Romero, M. R., Briz, Ó., & Marín, J. J. G. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1581605 · Cited by 25
López‐Ayllón, B. D., de Castro, J., Rodríguez‐Antolín, C., Pernía, O., de Cáceres, I. I., Belda-Iniesta, C., Perona, R., & Sastre, L. (2015) · PubMed · Cited by 24
Fu, H., Wu, Z., Lei, Z., Teng, Q., Yang, Y., Ashby, C. R., Lei, Y., Lian, Y., & Chen, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.861642 · Cited by 24
Self-citationThe nitrobenzoxadiazole derivative MC3181 blocks melanoma invasion and metastasis
Luca, A. D., Carpanese, D., Rapanotti, M. C., Viguria, T. M. S., Forgione, M., Rotili, D., Fulci, C., Iorio, E., Quintieri, L., Chimenti, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14690 · Cited by 22
Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx
Sissung, T. M., Ley, A. M., Strope, J. D., McCrea, E. M., Beedie, S., Peer, C. J., Shukla, S., van Velkinburgh, J. C., Reece, K. M., Troutman, S. M., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0477 · Cited by 20
The Role of Extracellular Vesicles in Mediating Resistance to Anticancer Therapies
Maleki, S., Jabalee, J., & Garnis, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084166 · Cited by 20
Possible Role of Cytochrome P450 1B1 in the Mechanism of Gemcitabine Resistance in Pancreatic Cancer
Yada, E., Kasajima, R., Niida, A., Imoto, S., Miyano, S., Miyagi, Y., Sasada, T., & Wada, S. (2021) · Biomedicines · doi:10.3390/biomedicines9101396 · Cited by 20
Alsinnawi, M., Zhang, A., Bianchi-Frias, D., Burns, J., Cho, E., Zhang, X., Sowalsky, A. G., Ye, H., Slee, A. E., True, L. D., et al. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-019-0141-6 · Cited by 19
Gachpazan, M., Kashani, H., Hassanian, S. M., Khazaei, M., Khorrami, S., Ferns, G. A., & Avan, A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191105114539 · Cited by 19
Haberkorn, B., Oswald, S., Kehl, N., Gessner, A., Taudte, R. V., Dobert, J. P., Zunke, F., Fromm, M. F., & König, J. (2022) · Molecular Pharmacology · doi:10.1124/molpharm.122.000539 · Cited by 19
Tiash, S., & Chowdhury, E. H. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1525388 · Cited by 18
Lu, K., Li, Z., Hu, Q., Sun, J., & Chen, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073623 · Cited by 18
Cited by
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells
Garg, P., Malhotra, J., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024) · Cancers · doi:10.3390/cancers16132478 · Cited by 339
Overcoming Barriers in Cancer Biology Research: Current Limitations and Solutions
(2025) · doi:10.3390/cancers17132102 · Cited by 44
Huo, X., Jiang, S., Wu, S., Lian, Q., & Chen, H. (2025) · Liver Research · doi:10.1016/j.livres.2025.01.002 · Cited by 12
Zahedifard, Z., Mahmoodi, S., & Ghasemian, A. (2025) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2738 · Cited by 12
Hypoxic microenvironment in cancer: role in metabolic reprogramming
Sureka, N., Maheshwari, R., Agravat, A., Singhal, S., Zaman, S., Rishi, B., Siraj, F., Zaheer, S., & Misra, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1771365 · Cited by 11
Metadata
- Authors
- Lei, Z., Tian, Q., Teng, Q., Wurpel, J. N. D., Zeng, L., Pan, Y., & Chen, Z.
- Venue
- MedComm
- Publisher
- Wiley
- Published
- 2023-05-22
- Volume
- 4
- Issue
- 3
- Pages
- e265-e265
- ISSN
- 2688-2663 (ISSN-L)
- OpenAlex
- W4378082489
- Cited by
- 347
- References
- 413
- FWCI
- 35.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.